Resiquimod (GMP)

Resiquimod (R848) (GMP) is Resiquimod (HY-13740) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist. Resiquimod (GMP) can induce human mMDSC to mature into inflammatory macrophages[1][2][3].

Product Specifications

CAS Number

[144875-48-9]

Product Name Alternative

R848 (GMP) ; S28463 (GMP)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Toll-like Receptor (TLR)

Type

GMP Small Molecules

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/resiquimod-gmp.html

Solubility

10 mM in DMSO

Smiles

OC(C)(C)CN1C(COCC)=NC2=C1C3=CC=CC=C3N=C2N

Molecular Formula

C17H22N4O2

Molecular Weight

314.38

Precautions

H302, H315, H319, H335

References & Citations

[1]Bayik D, et al. Factors Influencing the Differentiation of Human Monocytic Myeloid-Derived Suppressor Cells Into Inflammatory Macrophages. Front Immunol. 2018 Mar 26;9:608. |[2]Preisendörfer S, et al. FK506-Binding Protein 11 Is a Novel Plasma Cell-Specific Antibody Folding Catalyst with Increased Expression in Idiopathic Pulmonary Fibrosis. Cells. 2022 Apr 14;11 (8) :1341. |[3]Lee M, et al. Resiquimod, a TLR7/8 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells. Arch Pharm Res. 2014;37 (9) :1234-40.